| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
CK1δ 2.22 μM (IC50)
CK1-IN-3 targets casein kinase 1 delta (CK-1δ). CK1 is a serine/threonine kinase involved in multiple cellular processes, including circadian rhythm regulation, Wnt signaling, and DNA damage response. By inhibiting CK-1δ, the compound modulates these signaling pathways. The compound is an AC1 inhibitor with an IC50 of 2.22 µM for CK-1δ. |
|---|---|
| ln Vitro |
In cell-free biochemical assays, CK1-IN-3 inhibits CK-1δ with an IC50 of 2.22 µM. This activity demonstrates the compound's direct inhibition of CK-1δ enzymatic activity. The compound's selectivity for CK-1δ over other kinases can be assessed using kinase profiling assays. The compound can be used for the research of diseases related to circadian rhythm and inflammation.
|
| ln Vivo |
CK1-IN-3 (compound 35) (100 nM; feed), dramatically increases the lifespan of Drosophila to 36.17 days [2].
In cell-based assays, CK1-IN-3 has been shown to significantly extend the lifespan of Drosophila to 36.17 days when administered at 100 nM in feed. This effect is likely mediated through the modulation of circadian rhythm pathways. The compound's effects on CK-1δ activity and downstream signaling are evaluated in various cell lines. It can be used for the research of diseases related to circadian rhythm and inflammation. |
| Enzyme Assay |
The cell-free assay for CK1 inhibition involves measuring the kinase activity of purified CK-1δ enzyme in the presence of the compound. The assay uses a peptide substrate and ATP, and the phosphorylation of the substrate is measured using radioactivity, fluorescence, or luminescence. The IC50 of 2.22 µM is determined from dose-response curves.
|
| Cell Assay |
Cell-based assays for CK1-IN-3 involve culturing relevant cell lines and treating them with the compound at concentrations ranging from 0.01 to 100 µM. The compound's effects on CK-1δ activity are assessed by measuring the phosphorylation of downstream substrates by Western blotting. The effects on circadian rhythm can be assessed using reporter assays or by monitoring circadian gene expression. The compound's effects on cell viability and proliferation are also assessed.
|
| Animal Protocol |
In animal models, CK1-IN-3 has been evaluated for its effects on lifespan and circadian rhythm. In Drosophila, the compound significantly extended lifespan to 36.17 days when administered at 100 nM in feed. This suggests potential applications in aging and circadian rhythm research. Further studies in mammalian models would be required to assess its effects on circadian rhythm and inflammation-related diseases.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of CK1-IN-3 have not been extensively reported. As a small molecule with a molecular weight of 328.39 g/mol, the compound would be expected to have moderate oral bioavailability and tissue penetration. The compound is typically stored at -20°C, protect from light. Further pharmacokinetic studies would be required to determine plasma half-life, clearance, and metabolic pathways.
|
| Toxicity/Toxicokinetics |
CK1-IN-3 is intended for research use only and lacks established toxicity profiles for therapeutic applications. Standard laboratory safety precautions should be observed when handling this chemical reagent. As a CK1 inhibitor, the compound may have effects on circadian rhythm and cellular processes. Standard toxicity studies in rodents would be required to determine the safety profile if therapeutic development is pursued.
|
| References | |
| Additional Infomation |
CK1-IN-3 is a research-grade compound supplied for circadian rhythm and inflammation research. It is not an approved pharmaceutical and has no clinical trial history. The compound is a potent CK1 inhibitor with an IC50 of 2.22 µM for CK-1δ. It has been shown to extend lifespan in Drosophila. This product is intended for research use only.
|
| Molecular Formula |
C17H16N2O3S
|
|---|---|
| Molecular Weight |
328.386
|
| Exact Mass |
328.088
|
| CAS # |
349438-74-0
|
| PubChem CID |
670752
|
| Appearance |
Gray to brown solid powder
|
| LogP |
3.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
409
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1C=CC2N=C(SC=2C=1)NC(CC1=CC=CC=C1OC)=O
|
| InChi Key |
HFBLBLSJZDGKCC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H16N2O3S/c1-21-12-7-8-13-15(10-12)23-17(18-13)19-16(20)9-11-5-3-4-6-14(11)22-2/h3-8,10H,9H2,1-2H3,(H,18,19,20)
|
| Chemical Name |
N-(6-methoxy-1,3-benzothiazol-2-yl)-2-(2-methoxyphenyl)acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0452 mL | 15.2258 mL | 30.4516 mL | |
| 5 mM | 0.6090 mL | 3.0452 mL | 6.0903 mL | |
| 10 mM | 0.3045 mL | 1.5226 mL | 3.0452 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
